Northwestern University Researchers Identify Anti-Seizure Drug to Prevent Alzheimer's Plaques
Researchers at Northwestern University have discovered that levetiracetam, an FDA-approved anti-seizure drug, can prevent the formation of amyloid plaques associated with Alzheimer's disease. The study, published in Science Translational Medicine, reveals that levetiracetam stops the production of amyloid-beta 42 peptides, which are toxic protein fragments linked to Alzheimer's. The drug's effectiveness is contingent on early administration, potentially up to 20 years before symptoms appear, making it particularly beneficial for individuals at high genetic risk, such as those with Down syndrome. The research highlights a new mechanism that could open doors for additional drug targets. 
